Prevalence of SARS-CoV-2 antibodies in hemodialysis patients in Senegal: a multicenter cross-sectional study

Simple item page
dc.contributor.authorSeck, Sidy Mohamed
dc.contributor.authorMbow, Moustapha
dc.contributor.authorKane, Yaya
dc.date.accessioned2023-05-20T21:05:30Z
dc.date.available2023-05-20T21:05:30Z
dc.date.issued2021-11-17
dc.descriptionBMC nephrology, 22, 1-8.en_US
dc.description.abstractBackground: Hemodialysis patients are among high-risk groups for COVID-19. Africa is the continent with the lowest number of cases in the general population but we have little information about the disease burden in dialysis patients. Objectives: This study aimed to describe the seroprevalence of SARS-CoV-2 antibodies in the hemodialysis population of Senegal. Patients and methods: We conducted a multicenter cross-sectional survey, between June and September 2020 involving 10 public dialysis units randomly selected in eight regions of Senegal. After seeking their consent, we included 303 patients aged ≥ 18 years and hemodialysis for ≥ 3 months. Clinical symptoms and biological parameters were collected from medical records. Patients’ blood samples were tested with Abbott SARS-CoV-2 Ig G assay using an Architect system. Statistical tests were performed with STATA 12.0. Results: Seroprevalence of SARS-CoV-2 antibodies was 21.1% (95% CI = 16.7–26.1%). We noticed a wide variability in SARS-CoV-2 seroprevalence between regions ranging from 5.6 to 51.7%. Among the 38 patients who underwent nasal swab testing, only six had a PCR-confirmed infection and all of them did seroconvert. Suggestive clinical symptoms were reported by 28.1% of seropositive patients and the majority of them presented asymptomatic disease. After multivariate analysis, a previous contact with a confirmed case and living in a high population density region were associated with the presence of SARS-CoV-2 antibodies. Conclusion: This study presents to our knowledge the first seroprevalence data in African hemodialysis patients. Compared to data from other continents, we found a higher proportion of patients with SARS-CoV-2 antibodies but a lower lethality rate.en_US
dc.description.sponsorshipACEImpact: Environment and Health, CEA-AGIRen_US
dc.identifier.citationSeck, S. M., Mbow, M., Kane, Y., Cisse, M. M., Faye, G., Kama, A., ... & Mboup, S. (2021). Prevalence of SARS-CoV-2 antibodies in hemodialysis patients in Senegal: a multicenter cross-sectional study. BMC nephrology, 22, 1-8.en_US
dc.identifier.urihttps://doi.org/10.1186/s12882-021-02582-w
dc.identifier.urihttp://hdl.handle.net/123456789/1814
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.subjectMouhamadou Moustapha Cisseen_US
dc.subjectGnagna Fayeen_US
dc.subjectAdama Kamaen_US
dc.subjectMoussa Sarren_US
dc.subjectPamela Nitcheuen_US
dc.subjectMohamed Dahabaen_US
dc.subjectIbrahima Mbemba Dialloen_US
dc.subjectMame Selly Diawaraen_US
dc.subjectLotingo Nehemie Motoula Latouen_US
dc.subjectYacine Diaen_US
dc.subjectSouleymane Mboupen_US
dc.subjectSARS-CoV-2en_US
dc.subjectCOVID-19en_US
dc.subjectSeroprevalenceen_US
dc.subjectHemodialysisen_US
dc.subjectSenegalen_US
dc.subjectUniversity Cheikh Anta Diopen_US
dc.subjectCEA-AGIRen_US
dc.titlePrevalence of SARS-CoV-2 antibodies in hemodialysis patients in Senegal: a multicenter cross-sectional studyen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Prevalence of SARS-CoV-2 antibodies.pdf
Size:
1.1 MB
Format:
Adobe Portable Document Format
Description:
Main article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Environment